The APAC intravenous immunoglobulin market is expected to grow from US$ 2,609.61 million in 2022 to US$ 4,156.85 million by 2028. It is estimated to grow at a CAGR of 8.1% from 2022 to 2028.
Strong Pipeline Candidates for IVIG
Leading players in the intravenous immunoglobulin market have multiple projects, and many biological products in pipelines are based on proprietary technology. For instance, Evolve Biologics aims to manufacture and market plasma-derived therapeutics using its proprietary PlasmaCap EBA purification technology. The company is developing a portfolio of product candidates, IVIG, which completed its Phase III clinical trial in February 2021. Similarly, Biotest is a global company that offers plasma protein products and biotherapeutic drugs. The company is developing IgG Next Generation, a newly developed polyvalent immunoglobulin preparation for intravenous administration from human plasma to treat immunodeficiencies and autoimmune diseases. In September 2020, the company completed its phase III trial investigating IgG Next Generation for patients with primary immunodeficiency disease (PID). Thus, strong pipeline candidates for IVIG are expected to become a trend in the intravenous immunoglobulin market.
Market Overview
Asia Pacific (APAC) is the fastest-growing regional market for intravenous immunoglobulin. China, India, Japan, South Korea, Australia, and the Rest of APAC are the major contributors to the market in this region. Asia Pacific is likely to account for over 21.68% market share of the global intravenous immunoglobulin market in 2022 due to the increasing geriatric population, the rising prevalence of immune deficiency disorders, and the increasing adoption of immunoglobulin-based therapies for the treatment of primary immune deficiencies. Therefore, the region holds huge potential for the intravenous immunoglobulin market players to grow during the forecast period. China is a developing country in Asia Pacific with a well-established healthcare system and a fast-growing pharmaceutical industry. China is home to various medical, pharmaceutical, and biotechnology product manufacturing companies operating in the global market. China also has over 300 medical contract research organizations, along with prominent biopharmaceutical product manufacturers—including China Biologic Products Holdings, Inc. and Shanghai RAAS. These pharmaceutical companies are prone to global market competition, which encourages them to introduce innovative products, thereby boosting the growth of the intravenous immunoglobulin market.
APAC Intravenous Immunoglobulin Market Segmentation
The APAC intravenous immunoglobulin market is segmented into type, application, distribution channel, end user, and country. Based on type, the market is segmented into IgG, IgM, IgA, IgE, and IgD. The IgG segment registered the largest market share in 2022.
ADMA Biologics, Inc.; Bio Products Laboratory Ltd.; CSL Behring (CSL Limited); Grifols, S.A.; Kedrion S.p.A; Octapharma AG; Pfizer Inc.; Prothya Biosolutions B.V.; Shanghai RAAS; and Takeda Pharmaceutical Company Limited are among the leading companies operating in the intravenous immunoglobulin market in the region.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 2,609.61 Million |
| Market Size by 2028 | US$ 4,156.85 Million |
| CAGR (2022 - 2028) | 8.1% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By Type
|
|
Regions and Countries Covered
|
|
| Asia-Pacific | China, India, Japan, Australia, Rest of Asia-Pacific |
| Market leaders and key company profiles |
|
The Asia-Pacific Intravenous Immunoglobulin Market is valued at US$ 2,609.61 Million in 2022, it is projected to reach US$ 4,156.85 Million by 2028.
As per our report Asia-Pacific Intravenous Immunoglobulin Market, the market size is valued at US$ 2,609.61 Million in 2022, projecting it to reach US$ 4,156.85 Million by 2028. This translates to a CAGR of approximately 8.1% during the forecast period.
The Asia-Pacific Intravenous Immunoglobulin Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia-Pacific Intravenous Immunoglobulin Market report:
The Asia-Pacific Intravenous Immunoglobulin Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia-Pacific Intravenous Immunoglobulin Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia-Pacific Intravenous Immunoglobulin Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+1 646 791 7070
sales@businessmarketinsights.com
Get Free Sample For Asia-Pacific Intravenous Immunoglobulin Market
